
table of contents
概況
Today's session focused on progress in cannabinoid/cannabis-related research, with economic implications from the fields of clinical practice, formulation technology, and drug optimization.
In particular, the antibacterial potential of CB1 antagonists and liposomal synthesisCBDImproving bioavailability through subcutaneous administration of benzodiazepines and trends in the deprecation of high-risk psychotropic drugs (including medical cannabis) at pharmacies are topics that could impact pipeline development, supply and demand, and insurance and regulatory cost estimates.
| topic | Quantitative information/Key points | Economic implications |
|---|---|---|
| Antigonococcal activity of the CB1 antagonist ibipinabant | The most promising compound in the screening of 2,528 GPCR-related compounds. Strong activity against 20 strains of N. gonorrhoeae. Kills bacteria in 12 hours (below detection limit). Currently, no oral treatment/only intravenous ceftriaxone. | Accelerate technological exploration for developing new applications. Expanding resistance drives unmet market. Selective microbial profiling is expected to reduce side effect costs. |
| SynthesisCBDSubcutaneous administration of liposomes (dogs) | Randomized, blinded, placebo-controlled, crossover study. To address the issue of low bioavailability with oral administration, we aim for sustained release and high bioavailability. | Intellectual property value of formulation technology and delivery. Changing the administration route affects administration frequency, inventory turnover, and pricing. Room for differentiation in the animal healthcare market. |
| Pharmacy Deprescription (including medical cannabis) | A national survey of community pharmacists' practice, confidence, and perceptions. These include opioids, benzos, gabapentin, and medical cannabis. | Appropriate use and weight loss protocols have an impact on demand curves and insurance assessments. Involved in investment decisions regarding education and collaboration costs and guideline development. |
| A systematic review of natural therapies for oral disorders in palliative care | Efficacy, acceptability, adverse events, and oral tolerability were evaluated across multiple databases. PRISMA compliant/protocol registered. | Establishing a framework for evaluating natural products will contribute to establishing a basis for product selection and reimbursement negotiations. Contributing to improving the market quality of complementary and alternative therapies. |
Research/Clinical
CB1 antagonist ibipinabant, with potent bactericidal activity against Neisseria gonorrhoeae
In a screening of 2,528 GPCR-related compounds against Neisseria gonorrhoeae, the second most common cause of sexually transmitted diseases in the world, the CB1 receptor antagonist ibipinabant showed the most potent antigonococcal activity.
Activity was confirmed against 20 clinical isolates, and it was also shown not to inhibit Lactobacillus species, which are some of the most common vaginal flora.
Time-kill tests have confirmed bactericidal activity, reducing bacterial counts to below the detection limit within 12 hours.
Currently, there is no oral treatment and ceftriaxone (injection) is the only FDA-approved treatment, and as reports of resistant strains increase internationally, the value of developing this drug as a potential new mechanism is particularly evident.
Economically, the magnitude of unmet medical need directly justifies the investment in clinical development, and a selective microbial profile may mitigate regulatory and pricing risks through an improved safety profile.
(https://pubmed.ncbi.nlm.nih.gov/41636526/)
CB1 antagonists are compounds that have pharmacological effects by blocking the "cannabinoid receptor 1" on which endogenous cannabinoids act.
This report demonstrates the possibility of a non-central domain of action known as "antibacterial activity," and is a good example of the intersection of pharmacology and microbiology.
Liposomal formulation of synthetic CBD for sustained release and high bioavailability via subcutaneous administration (dogs)
While oral CBD is said to have low bioavailability due to the first-pass effect, efficacy, pharmacokinetics, and safety were evaluated in a randomized, blinded, placebo-controlled, crossover clinical trial (dogs) in which CBD was encapsulated in liposomes and administered subcutaneously.
Based on findings from previous pilot studies (sustained release, high bioavailability, analgesia), the key to practical application is appropriate sustained release and pharmacokinetics.
Results in the field of animal medicine can also affect the patent and license value of formulation technology and the design of translational research for human use.
(https://pubmed.ncbi.nlm.nih.gov/41635790/)
Liposomes are a delivery technology that encapsulates drugs in a lipid bilayer, allowing for controlled release and improved tissue targeting.
From a pharmacoeconomic perspective, sustained effective blood concentrations can lead to less frequent dosing, optimizing adherence and inventory turnover.
Systematic review of natural therapies for oral disorders in palliative care
A PRISMA-compliant review was published that assessed the efficacy, acceptability, adverse events, and oral tolerability of natural products across multiple databases.
The JBI tool and Oxford levels of evidence are used to assess the quality of evidence, and progress is being made in establishing a framework for clinical implementation.
Natural products are often the subject of formulary selection and reimbursement discussions, and the business issue is how to balance the costs of standardization and quality control with the potential for improved outcomes through increased patient acceptability.
(https://pubmed.ncbi.nlm.nih.gov/41636367/)
Complementary and alternative medicines face challenges in terms of variations in primary ingredients and standardization of production.
Reproducibility of quality is directly linked to the external validity of observational studies and also affects the evaluations of regulatory authorities and insurers.
Regulation/Policy
Deprecation status of community pharmacists (including medical cannabis)
A nationwide survey of pharmacists' practices, confidence, and perspectives regarding the deprescribing of high-risk psychotropic medications, including opioids, benzodiazepines, gabapentins, and medical cannabis.
The implementation of on-site dosage reduction and discontinuation protocols impacts healthcare finances by reducing adverse events and optimizing medication costs.
At the same time, costs are required to establish educational programs and multi-disciplinary collaboration, as well as operational costs for developing guidelines.
(https://pubmed.ncbi.nlm.nih.gov/41636468/)
Deprescription is the process of reducing or discontinuing a medication based on a reassessment of its effectiveness and risks.
When medical cannabis is used, it is important to evaluate multiple factors, including indications, interactions, and risk of addiction.
Companies/Markets
Drug delivery and new indications are investment themes
Although the materials do not disclose company names or funding sources, the following technologies and application areas may be subject to licensing or collaborative research.
- Repurposing CB1 antagonists in the antibacterial space.
- Changing the administration route and sustained release of CBD using liposomal formulations.
- Standardization and evaluation system for natural products for palliative care.
These drugs have the potential for commercialization, reimbursement negotiations, and international expansion, subject to clarification of regulatory requirements and accumulation of evidence.
(41636526,41635790,41636367)
Suggestions for market and demand trends
Although the material does not include quantitative market size, price, or stock price information, the following supply and demand and cost factors are suggested:
- The demand for new antibiotics is becoming apparent due to the spread of resistant bacteria (the lack of oral options is increasing the unmet need).
- Possibility of redesigning adherence, inventory, and pricing strategies by optimizing CBD administration routes.
- The spread of deprescrip- tion will require a review of prescription trends and will require increased education and coordination costs.
(41636526,41635790,41636468)
The intersection of terminology and scholarship
Discipline (random): Operations Research.
Commonalities: Pharmacokinetic improvement and deprescription protocol design can be formulated as an optimization problem under constraints, leading to mathematical decision-making that simultaneously considers inventory, administration schedules, and risk minimization.
Today's highlights
- The CB1 antagonist ibipinabant emerged as the leading candidate for antigonococcal activity in a screening of 2,528 compounds, demonstrating activity against 20 strains and bactericidal activity within 12 hours.
- Liposomal subcutaneous delivery of synthetic CBD is being considered for clinical trial design as a solution to the bioavailability challenges of oral administration.
- A nationwide survey of the actual state of deprescription (including medical cannabis) at pharmacies will encourage discussion on demand, education costs, and governance design.
Collection List
- Identification of the cannabinoid receptor 1 antagonist, ibipinabant, as a potent inhibitor of Neisseria gonorrhoeae (https://pubmed.ncbi.nlm.nih.gov/41636526/)
- Community pharmacists' practices and perspectives on deprescribing high-risk psychotropic medicines: National survey findings (https://pubmed.ncbi.nlm.nih.gov/41636468/)
- Natural Treatments for Oral Disorders in Palliative Care: A Systematic Review (https://pubmed.ncbi.nlm.nih.gov/41636367/)
- Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial (https://pubmed.ncbi.nlm.nih.gov/41635790/)

![Mail-order product: MDMA × MM Analog [For Research Use]](https://www.thch-vape.shop/html/user_data/assets/img/products/213_250x250.webp)


